‘Doing more with less’: In-house counsel on budgets and strategy

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

16 October 2026 All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.

Biotech

Scientist and Chinese biotech targeted by Beam in secrets suit

29 September 2026 The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.

Biotech

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

21 September 2026 Judges agreed with the Oxford University spin-out that MGI Tech was likely to infringe Oxford’s patent, and banned sales of certain Cyclone devices to preserve the one-player-market status quo.

More features

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

Amarin and Hikma call time on six-year skinny label fight

WATCH: Medmix global IP head on building business-focused IP teams

Fish & Richardson hires duo with ‘sophisticated’ tech patent expertise

Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

Align Technology notches another win in escalating clear aligner feud

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

‘Doing more with less’: In-house counsel on budgets and strategy

More on this story

Editor's picks

Editor's picks

More features